Transplant Center, Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Arch Iran Med. 2010 Sep;13(5):417-9.
Post-transplantation lymphoproliferative disorders (PTLD) are a spectrum of diseases defined as polyclonal or monoclonal proliferations of lymphocytes which occur after solid organ transplants. In this study, we report our first experiences with PTLD following liver transplantation in Iran.
We retrospectively analyzed five cases of PTLD which followed liver transplantation among more than 550 liver transplants in our center. Of these, three were pediatric cases and two were adults. The underlying causes were tyrosinemia, autoimmune hepatitis, and progressive familial intrahepatic cholestasis (PFIC) in the three pediatric cases. HCV hepatitis was the primary cause for cirrhosis in one of the adults and the other adult was labeled as cryptogenic cirrhosis. All cases, except for one, developed PTLD during the first year following liver transplantation.
Patients were diagnosed as PTLD, B-cell, MALT and Hodgkin-like (according to the WHO classification of PTLD). The three pediatric patients died despite discontinuation of immunosuppressive drugs and chemotherapy. Fortunately both adult patients, until now, are still alive.
The incidence of PTLD in our center is lower than previous reports from other centers (0.9%), with a 60% mortality rate and worse prognosis in the pediatric age group.
移植后淋巴组织增生性疾病(PTLD)是一组疾病,定义为实体器官移植后发生的淋巴细胞多克隆或单克隆增生。在本研究中,我们报告了在伊朗进行肝移植后发生的首例 PTLD 病例。
我们回顾性分析了在我们中心进行的 550 多例肝移植中发生的 5 例 PTLD 病例。其中 3 例为儿科病例,2 例为成人病例。在 3 例儿科病例中,潜在病因分别为酪氨酸血症、自身免疫性肝炎和进行性家族性肝内胆汁淤积症(PFIC)。1 例成人的肝硬化是由 HCV 肝炎引起的,另 1 例成人被归类为隐源性肝硬化。除 1 例外,所有病例均在肝移植后第一年发生 PTLD。
根据 WHO 对 PTLD 的分类,患者被诊断为 B 细胞、MALT 和霍奇金样 PTLD。尽管停用了免疫抑制剂和化疗,3 例儿科患者仍死亡。幸运的是,截至目前,2 例成年患者仍然存活。
我们中心的 PTLD 发生率低于其他中心的既往报告(0.9%),死亡率为 60%,儿科年龄组的预后更差。